Clinical-stage immuno-oncology company Agenus Inc. (NASDAQ: AGEN) announced an agreement under which Bristol-Myers Squibb Co. (BMY) will be granted a global exclusive license to its proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target.
AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity.
Under terms of the agreement, Agenus will receive a $200 million upfront payment and up to $1.36 billion in development, regulatory and commercial milestones plus royalties on net product sales.
Agenus expects to file an Investigational New Drug application for the development of AGEN1777 with the FDA in the second quarter of 2021.
In addition, Bristol Myers Squibb intends to advance the research and development of AGEN1777 in immuno-oncology for high priority tumor indications including non-small cell lung cancer.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.